Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from iX Biopharma Ltd. ( (SG:42C) ).
iX Biopharma Ltd. has announced the issuance and allotment of 2,914,771 new ordinary shares to three directors, increasing the total number of issued shares to 887,959,445. This move, which slightly dilutes existing shares by 0.33%, is expected to enhance the company’s governance structure and align the interests of the directors with those of shareholders, potentially impacting the company’s market positioning positively.
More about iX Biopharma Ltd.
iX Biopharma Ltd. is a company incorporated in Singapore, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative therapies, primarily targeting the pharmaceutical and healthcare markets.
Average Trading Volume: 291,434
Technical Sentiment Consensus Rating: Buy
Current Market Cap: S$20.36M
For an in-depth examination of 42C stock, go to TipRanks’ Stock Analysis page.